Dyskinesia - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 102 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Dyskinesia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Dyskinesia - Pipeline Review, H2 2014', provides an overview of the Dyskinesia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyskinesia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dyskinesia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dyskinesia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dyskinesia Overview 9
Therapeutics Development 10
Pipeline Products for Dyskinesia - Overview 10
Pipeline Products for Dyskinesia - Comparative Analysis 11
Dyskinesia - Therapeutics under Development by Companies 12
Dyskinesia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Dyskinesia - Products under Development by Companies 17
Dyskinesia - Companies Involved in Therapeutics Development 18
XenoPort, Inc. 18
Novartis AG 19
BioMarin Pharmaceutical Inc. 20
Addex Therapeutics Ltd 21
Avanir Pharmaceuticals, Inc. 22
Catalyst Pharmaceutical Partners, Inc. 23
Neurim Pharmaceuticals Ltd 24
Santhera Pharmaceuticals Holding AG 25
Upsher-Smith Laboratories, Inc. 26
Osmotica Pharmaceutical Corp. 27
Adamas Pharmaceuticals, Inc. 28
Targacept, Inc. 29
Heptares Therapeutics Ltd. 30
Amarantus Bioscience Holdings, Inc. 31
SciFluor Life Sciences, LLC 32
SK Biopharmaceuticals Co., Ltd. 33
Merz Pharmaceuticals GmbH 34
Neurolixis Inc. 35
Contera Pharma ApS 36
Dyskinesia - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 42
Assessment by Route of Administration 45
Assessment by Molecule Type 46
Drug Profiles 47
amantadine hydrochloride ER - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
amantadine hydrochloride ER - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AQW-051 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
dipraglurant IR - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
eltoprazine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
fipamezole - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AVP-786 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
JM-010 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Neu-120 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SKL-PD - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
naluzotan - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CPP-115 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecule Targeting mGluR5 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
acamprosate Prodrug - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Neu-240 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
befiradol - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MRZ-8676 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
RGFP-109 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
TC-8831 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
IRL-790 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule for Dyskinesia and Hyperkinesia - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecule For Dyskinesia - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules to Antagonize Metabotropic Glutamate Receptor 5 (mGluR5) for Dyskinesia - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Dyskinesia - Recent Pipeline Updates 77
Dyskinesia - Dormant Projects 92
Dyskinesia - Discontinued Products 93
Dyskinesia - Product Development Milestones 94
Featured News & Press Releases 94
Jun 11, 2014: Neurocrine Biosciences Presenting NBI-98854 Scientific Abstracts And Posters At The International Parkinson And Movement Disorder Society's 18th Annual Congress 94
Jun 10, 2014: Adamas Pharmaceuticals Announces Rater Training Data on ADS-5102 for Parkinson's Disease Patients with Levodopa-Induced Dyskinesia 94
Jun 09, 2014: United States Patent Issued To Adamas Pharmaceuticals 95
Apr 30, 2014: Adamas Pharmaceuticals Provides Data Update On ADS-5102 At The American Academy Of Neurology Annual Meeting 96
Apr 23, 2014: Adamas Pharmaceuticals Announces Data Update At American Academy Of Neurology Annual Meeting 97
Mar 19, 2014: Santhera Receives US Patent for Fipamezole in the Treatment of Neurodegenerative Diseases 97
Oct 22, 2013: Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease 98
Oct 02, 2013: Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinson's Congress 98
Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt 100
Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 102
Disclaimer 102

List of Tables
Number of Products under Development for Dyskinesia, H2 2014 10
Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Dyskinesia - Pipeline by XenoPort, Inc., H2 2014 18
Dyskinesia - Pipeline by Novartis AG, H2 2014 19
Dyskinesia - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 20
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2014 21
Dyskinesia - Pipeline by Avanir Pharmaceuticals, Inc., H2 2014 22
Dyskinesia - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2014 23
Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2014 24
Dyskinesia - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2014 25
Dyskinesia - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 26
Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp., H2 2014 27
Dyskinesia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 28
Dyskinesia - Pipeline by Targacept, Inc., H2 2014 29
Dyskinesia - Pipeline by Heptares Therapeutics Ltd., H2 2014 30
Dyskinesia - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 31
Dyskinesia - Pipeline by SciFluor Life Sciences, LLC, H2 2014 32
Dyskinesia - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 33
Dyskinesia - Pipeline by Merz Pharmaceuticals GmbH, H2 2014 34
Dyskinesia - Pipeline by Neurolixis Inc., H2 2014 35
Dyskinesia - Pipeline by Contera Pharma ApS, H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Assessment by Combination Products, H2 2014 38
Number of Products by Stage and Target, H2 2014 41
Number of Products by Stage and Mechanism of Action, H2 2014 44
Number of Products by Stage and Route of Administration, H2 2014 45
Number of Products by Stage and Molecule Type, H2 2014 46
Dyskinesia Therapeutics - Recent Pipeline Updates, H2 2014 77
Dyskinesia - Dormant Projects, H2 2014 92
Dyskinesia - Discontinued Products, H2 2014 93